Skip to content

Oruka Therapeutics, Inc. ORKA Deferred Tax Assets, Gross

Deferred Tax Assets, Gross at other companies

Corebridge Financial logo
Corebridge FinancialCRBG
$7.82B-13.6%
Bank of America logo
Bank of AmericaBAC
$24.18B-5.9%
MSCI logo
MSCIMSCI
$191.15M+1.9%
Arthur J. Gallagher logo
Arthur J. GallagherAJG
$2.73B+48.6%
American International Group logo
American International GroupAIG
$5.88B-9.6%
PNC Financial Services logo
PNC Financial ServicesPNC
$3.52B-25.0%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsGross.

The official record: Oruka Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s deferred tax assets, gross.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s deferred tax assets, gross?
Oruka Therapeutics, Inc. (ORKA) reported deferred tax assets, gross of $49.14M in Q4 2025.